Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
HCRN GU16-260
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
- NCT03117309 ↗
- Completed
- Michael B. Atkins, MD
- Standard
We haven't built an HCP commentary report on HCRN GU16-260 (nivolumab and ipilimumab in Advanced Renal Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HCRN GU16-260 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 13 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- Nivolumab 240 mg; Ipilimumab 1mg/kg; Nivolumab 3mg/kg; Nivolumab 360mg
- Arms
- PART A: Nivolumab · Experimental
- PART B: Nivolumab + Ipilimumab · Experimental
- Enrollment
- 164
- Primary outcomes
- 1-year Progression Free Survival (PFS) Rate for ccRCC Patients
- Sponsor
- Michael B. Atkins, MD with Bristol-Myers Squibb, Hoosier Cancer Research Network
- Start
- Apr 24, 2017
- Primary completion
- Mar 25, 2022
- Results posted
- Yes
- Registry record
- NCT03117309 · updated Jul 10, 2025
Publications
linked from the registry- Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). J Immunother Cancer. 2023 Mar;11(3):e004780. doi: 10.1136/jitc-2022-004780. PubMed 36948504
- Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022 Sep 1;40(25):2913-2923. doi: 10.1200/JCO.21.02938. Epub 2022 Apr 20. PubMed 35442713